Photodynamic inactivation of a RNA-virus model using water-soluble β-octa-Substituted pyridinium-pyrazolyl phthalocyanines
Source abstract
Abstract
Among the various groups of microorganisms, viruses have generally a greater capacity for mutation, especially RNA viruses, as was demonstrated by SARS-CoV2 virus mutations. This high mutation rate promotes the development of their resistance to traditional antivirals and establishes the resistance behaviour in virus populations, decreasing their susceptibility to these drugs. In this context, the photodynamic treatment appears as a potentially effective method against microorganisms and, considering its mode of action is not likely to lead to the development of resistance. In this work, two newly zinc(II) phthalocyanines (ZnPcs) bearing pyridinium-pyrazolyl groups (2a and 3a) were synthesized, characterized, and applied in photodynamic inactivation (PDI) of bacteriophage Φ6 (or Phage Phi6) as a RNA-virus model. These quaternized dyes were applied at different concentrations (from 5.0 to 20 μM, and under white light irradiation in the irradiance range between 50 and 150 mW/cm2) to test their efficiency for possible clinical or environmental applications. The results showed that the new cationic ZnPcs 2a and 3a efficiently inactivate the RNA-virus model (bacteriophage Φ6), even at the lowest tested irradiance. These compounds are thus promising photosensitizers to be used in various contexts.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Photodynamic Therapy Research Studies · Nanoplatforms for cancer theranostics · Biosensors and Analytical Detection
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (68)
Show source-provided references
1. Complexities of viral mutation rates10.1128/JVI.01031-17 ↗
2. Genomes
3. Genetic instability of RNA viruses
4. Virus evolution and genetics
5. Viral fitness: definitions, measurement, and current insights10.1016/j.coviro.2012.07.007 ↗
6. Viral evolution
7. Pathogenesis of virus infections
8. The evolution of seasonal influenza viruses10.1038/nrmicro.2017.118 ↗
9. Potential emergence of antiviral-resistant pandemic viruses via environmental drug exposure of animal reservoirs10.1021/acs.est.0c03105 ↗
10. Antiviral drug resistance as an adaptive process10.1093/ve/vew014 ↗
11. Antimicrobial photodynamic inactivation: a bright new technique to kill resistant microbes10.1016/j.mib.2016.06.008 ↗
12. Antimicrobial photodynamic inactivation and photodynamic therapy for infections10.1007/978-1-60761-697-9_12 ↗
13. Photodynamic inactivation of Candida albicans in blood plasma and whole blood10.3390/antibiotics8040221 ↗
14. Photodynamic inactivation of Escherichia coli with cationic ammonium Zn(ii) phthalocyanines10.1039/c5pp00147a ↗
15. Pyrazole-pyridinium porphyrins and chlorins as powerful photosensitizers for photoinactivation of planktonic and biofilm forms of E. Coli10.1016/j.dyepig.2021.109557 ↗
16. Photoinactivation of phage Phi6 as a SARS-CoV-2 model in wastewater: evidence of efficacy and safety10.3390/microorganisms10030659 ↗
17. Antimicrobial photodynamic approach in the inactivation of viruses in wastewater: influence of alternative adjuvants10.3390/antibiotics10070767 ↗
18. Trends and targets in antiviral phototherapy10.1039/c9pp00211a ↗
19. Organic photosensitizers for antimicrobial phototherapy10.1039/D1CS00647A ↗
20. Organic photo-antimicrobials: principles, molecule design, and applications10.1021/jacs.1c08679 ↗
21. Cationic phthalocyanine dendrimers as potential antimicrobial photosensitisers10.1039/C7OB02270K ↗
22. Occurrence of various viruses and recent evidence of SARS-CoV-2 in wastewater systems10.1016/j.jhazmat.2021.125439 ↗
23. Elimination of SARS-CoV-2 along wastewater and sludge treatment processes
24. Photoantimicrobials—an update10.1002/tbio.201900033 ↗
25. Versatile thiopyridyl/pyridinone porphyrins combined with potassium iodide and thiopyridinium/methoxypyridinium porphyrins on E. Coli photoinactivation10.1016/j.dyepig.2020.108476 ↗
26. Photoinactivation of Escherichia coli with water-soluble ammonium-substituted phthalocyanines10.1021/acsabm.0c00128 ↗
27. Photophysics and photochemistry of photodynamic therapy: fundamental aspects10.1007/s10103-008-0539-1 ↗
28. Recent update: antimicrobial agents containing pyrazole nucleus10.22159/ajpcr.2018.v11i12.29418 ↗
29. Can light-based approaches overcome antimicrobial resistance?10.1002/ddr.21453 ↗
30. Advances in antimicrobial photodynamic inactivation at the nanoscale10.1515/nanoph-2016-0189 ↗
31. Unsymmetrical cationic porphyrin-cyclodextrin bioconjugates for photoinactivation of Escherichia coli10.1016/j.pdpdt.2020.101788 ↗
32. In vitro photodynamic treatment of Fusarium oxysporum conidia through the action of thiopyridinium and methoxypyridinium chlorins10.1016/j.jphotochem.2022.114081 ↗
33. Comparative photodynamic inactivation of bioluminescent E. Coli by pyridinium and inverted pyridinium chlorins10.1016/j.dyepig.2019.03.021 ↗
34. Overview of cationic phthalocyanines for effective photoinactivation of pathogenic microorganisms10.1016/j.jphotochemrev.2021.100422 ↗
35. Photodynamic inactivation of pathogenic gram-negative and gram-positive bacteria mediated by Si(IV) phthalocyanines bearing axial ammonium units10.1016/j.jphotobiol.2022.112502 ↗
36. In vitro photoinactivation of Fusarium oxysporum conidia with light-activated ammonium phthalocyanines10.3390/ijms24043922 ↗
37. Porphyrins and phthalocyanines: photosensitizers and photocatalysts
38. Axially decorated SiIV-phthalocyanines bearing mannose- or ammonium-conjugated siloxanes: comparative bacterial labeling and photodynamic inactivation10.1111/php.12881 ↗
39. Synthesis and photophysicochemical properties of novel axially di-substituted silicon (IV) phthalocyanines and their photodynamic antimicrobial chemotherapy (PACT) activity against Staphylococcus aureus10.1016/j.synthmet.2019.116203 ↗
40. Inverted methoxypyridinium phthalocyanines for PDI of pathogenic bacteria10.1039/c5pp00145e ↗
41. Photoinactivation of planktonic and biofilm forms of Escherichia coli through the action of cationic zinc(II) phthalocyanines10.1002/cptc.201900020 ↗
42. Meso-substituted cationic porphyrins as efficient photosensitizers of gram-positive and gram-negative bacteria10.1016/1011-1344(95)07147-4 ↗
43. Photoinactivation of bacteria. Use of a cationic water-soluble zinc phthalocyanine to photoinactivate both gram-negative and gram-positive bacteria10.1016/1011-1344(95)07148-2 ↗
44. Phthalocyanines. Part VI. The structure of the phthalocyanines10.1039/jr9340001033 ↗
45. The surprisingly positive effect of zinc-phthalocyanines with high photodynamic therapy efficacy of melanoma cancer10.3389/fchem.2022.825716 ↗
46. An effective and potentially safe blood disinfection protocol using tetrapyrrolic photosensitizers10.4155/fmc-2016-0217 ↗
47. Amphiphilic phthalocyanine-cyclodextrin conjugates for cancer photodynamic therapy10.1039/C4CC02226B ↗
48. Assessing amphiphilic ABAB Zn(II) phthalocyanines with enhanced photosensitization abilities in in vitro photodynamic therapy studies against cancer10.3390/molecules25010213 ↗
49. The unique features and promises of phthalocyanines as advanced photosensitisers for photodynamic therapy of cancer10.1039/C9CS00129H ↗
50. Susceptibility of non-enveloped DNA- and RNA-type viruses to photodynamic inactivation10.1039/c2pp25156f ↗
51. Evaluation of photodynamic therapy agents through transient grating measurements10.1021/jp022646e ↗
52. Unique multiphthalocyanine coordination systems: vibrationally hot excited states and charge transfer states that power high energy triplet charge separated states10.1039/D2NR03721A ↗
53. Cunha photodynamic inactivation of the phytopathogenic bacterium xanthomonas citri subsp
54. The antimicrobial photoinactivation effect on Escherichia coli through the action of inverted cationic porphyrin–cyclodextrin conjugates10.3390/microorganisms10040718 ↗
55. Thiopyridinium phthalocyanine for improved photodynamic efficiency against pathogenic fungi10.1016/j.jphotobiol.2022.112459 ↗
56. In vitro photosensitizing efficacy of cationic phthalocyanine derivatives against C. Albicans: effect of serum albumins10.1142/S1088424605000575 ↗
57. United States envirnomental protection agency EPA United States environmental protection agency. Pesticide Registration - Guidance for Products Adding Residual Efficacy Claims.
58. Sewage bacteriophage inactivation by cationic porphyrins: influence of light parameters10.1039/c0pp00051e ↗
59. Photodynamic inactivation of mammalian viruses and bacteriophages10.3390/v4071034 ↗
60. Survival of the enveloped bacteriophage Phi6 (a surrogate for SARS-CoV-2) in evaporated saliva microdroplets deposited on glass surfaces10.1038/s41598-020-79625-z ↗
61. Systematic review and meta-analysis of the persistence and disinfection of human coronaviruses and their viral surrogates in water and wastewater10.1021/acs.estlett.0c00313 ↗
62. Evaluation of Phi6 persistence and suitability as an enveloped virus surrogate10.1021/acs.est.7b01296 ↗
63. Persistence of bacteriophage Phi 6 on porous and nonporous surfaces and the potential for its use as an ebola virus or coronavirus surrogate10.1128/AEM.01482-20 ↗
64. Survivability, partitioning, and recovery of enveloped viruses in untreated municipal wastewater10.1021/acs.est.6b00876 ↗
65. Evaluation of resistance development and viability recovery by a non-enveloped virus after repeated cycles of APDT10.1016/j.antiviral.2011.06.007 ↗
66. Photodynamic inactivation of microorganisms in different water matrices: the effect of physicochemical parameters on the treatment outcome10.1016/j.scitotenv.2022.160427 ↗
67. Armarego · 2013
68. Cationic versus anionic phthalocyanines for photodynamic therapy: what a difference the charge makes10.1021/acs.jmedchem.0c00481 ↗